Amgen Inc.
corporate_fare Company Profile
Amgen Inc. (NASDAQ:AMGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 54 items for AMGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for AMGN spans 10-Q, 8-K.
Recent high-impact activity:
- Amgen Beats Q3, Lifts Guidance as Three Trials Hit Endpoints
- Amgen 10-Q: Q3 Revenue $10.4B, Diluted EPS $7.08; TAVNEOS and IRS Disputes Detailed
- Amgen Q3 Revenue Up 8% to $10.4B, Full-Year Guidance Raised to $38.9-39.7B
- Amgen Posts $6.45 Adjusted EPS for Third Quarter
- Imdelltra-Imfinzi Combo Cuts Death Risk 58% in First-Line Small-Cell Lung Cancer
Financial Snapshot
Short Interest & Short Volume
4.97 days to coverFINRA reported short interest of 12,592,756 shares in AMGN as of the October 30, 2026 settlement, a 5.9% decrease from the prior period — about 5.0 days to cover at its recent average daily volume. On November 20, 2026, 54.0% of AMGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.